Opko Health, Inc. – ‘NTN 10K’ for 6/30/96

As of:  Tuesday, 3/31/98   ·   For:  6/30/96   ·   Accession #:  950116-98-724   ·   File #:  0-26078

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Notice of a Late Filing of a Form 10-K (Late Notice)   —   Rule 12b-25
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NTN 10K     Notice of a Late Filing of a Form 10-K (Late           4     13K 
                          Notice)                                                

NTN 10K
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 FORM 12b-25

                                                  Commission File Number 0-26918

 Notification of Late Filing

(Check one):            |X| Form 10-KSB         [ ] Form 11-K 
                   [ ] Form 20-F    [ ] Form 10-QSB   [ ] Form N-SAR

For Period Ended:   December 31, 1997                         
------------------    

[ ] Transition Report on Form 10-KSB        [ ] Transition Report on Form 10-QSB
[ ] Transition Report on Form 20-F          [ ] Transition Report on Form N-SAR 
[ ] Transition Report on Form 11-K                                              

        For the Transition Period Ended: _____________________________________

        Read Attached Instruction Sheet Before Preparing Form. Please Print or
Type.                                                                           

      Nothing in this Form shall be construed to imply that the Commission
has verified any information contained herein.                                  

       If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates: _______________________ 
_______________________________________________________________________________ 

PART I
REGISTRANT INFORMATION

Full name of registrant Cytoclonal Pharmaceutics Inc.                           
------------------------------  
Former name if applicable                                                       

________________________________________________________________________________

Address of principal executive office (Street and Number)                       

 9000 Harry Hines Boulevard, Suite 330
--------------------------------------------------------------------------------

City, state and zip code Dallas, Texas 75235                                    
-------------------           

 PART II
RULE 12b-25(b) AND (c)

         If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the         
following should be completed. (Check box if appropriate.)                      

            (a) The reasons described in reasonable detail in Part III of this
             Form could not be eliminated without unreasonable effort or
expense;                                      

NTN 10K
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd
       (b) The subject annual report, semi-annual report, transition
            report on Forms 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or
              portion thereof will be filed on or before the 15th calendar
       day following the prescribed due date; or the subject
    [X]         quarterly report or transition report on Form 10-Q, 10-QSB, or
               portion thereof will be filed on or before the fifth calendar
day following the prescribed due date; and    

          (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.    

PART III
 NARRATIVE

      State below in reasonable detail the reasons why Forms 10-K, 10-KSB,
11-K, 20-F, 10-Q, 10-QSB, N-SAR or the transition report portion thereof could  
not be filed within the prescribed time period.                                 

      The registrant's independent auditors are currently conducting their
year-end audit and are unable to meet the Form 10-KSB March 31, 1998 filing     
deadline. Once such auditors have completed their audit, the registrant will    
file Form 10-KSB. See Exhibit A attached hereto.                                

 PART IV
 OTHER INFORMATION

      (1) Name and telephone number of person to contact in regard to this
notification.                                                                   

Robert H. Cohen, Esq.                       (212) 735-8680
        ---------------------              -------------------------------
        (Name)                             (Area Code)  (Telephone Number)

        (2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company  
Act of 1940 during the preceding 12 months or for such shorter period that the  
registrant was required to file such report(s) been filed? If the answer is no, 
identify report(s).                                                             

                                                                  |X| Yes [ ] No

 (3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be       
reflected by the earnings statements to be included in the subject report or    
portion thereof?                                                                

                                                                  | | Yes [X] No

If so: attach an explanation of the anticipated change, both  
narratively and quantitatively, and, if appropriate, state the reasons why a    
reasonable estimate of the results cannot be made.                              

NTN 10K
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd
 Cytoclonal Pharmaceutics Inc.
--------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.                                          

Date:    March 31, 1998        By:         /s/Arthur P. Bollon                  
     ---------------------         ---------------------------------------------
                             Arthur P. Bollon, Ph.D., Chairman and President

    Instruction. The Form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title of
the person signing the Form shall be typed or printed beneath the signature. If 
the statement is signed on behalf of the registrant by an authorized            
representative (other than an executive officer), evidence of the               
representative's authority to sign on behalf of the registrant shall be filed   
with the Form.                                                                  

 ATTENTION

   Intentional misstatements or omissions of fact constitute Federal
criminal violations (see 18 U.S.C. 1001).                                       

NTN 10K
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th
                                                                       Exhibit A

Richard A. Eisner & Company, LLP
[Letterhead]

March 30, 1998

Dr. Arthur Bollon                                                               
Cytoclonal Pharmaceutics, Inc.                                                  
9000 Harry Hines Boulevard                                                      
Dallas, Texas   75235                                                           

Dear Dr. Bollon:                                                                

         Pursuant to your request, please be advised that pending receipt of the
requested cash flow projection information, we are unable to complete our audit 
of the Company's financial statements as of and for the year ended December 31, 
1997.                                                                           

Very truly yours,   

 /s/Richard P. Shanley
                     -----------------------------------------
       Richard P. Shanley, Partner

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘NTN 10K’ Filing		Date		First		Last			Other Filings
Filed on:		3/31/98		2		3			10QSB
		3/30/98		4					SC 13D
		12/31/97		1		4			10KSB40
For Period End:		6/30/96							10-Q
									List all Filings